Published in JAMA on February 19, 2003
Digoxin In Treatment of Alcohol Associated Hepatitis (DIGIT-AlcHep) | NCT05014087
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol (2014) 3.09
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ (2015) 2.40
Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J (2008) 2.29
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Digoxin associates with mortality in ESRD. J Am Soc Nephrol (2010) 1.66
Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol (2007) 1.66
Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med (2013) 1.61
Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail (2013) 1.41
[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24
Cardiomyopathy, familial dilated. Orphanet J Rare Dis (2006) 1.14
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol (2008) 1.14
Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci (2007) 1.13
Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol (2008) 1.07
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev (2009) 1.02
Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol (2013) 1.01
Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart (2004) 0.98
[Heart diseases in pregnancy]. Clin Res Cardiol (2008) 0.96
Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol (2008) 0.96
Reduction of Na/K-ATPase potentiates marinobufagenin-induced cardiac dysfunction and myocyte apoptosis. J Biol Chem (2012) 0.95
The underuse of digoxin in heart failure, and approaches to appropriate use. CMAJ (2007) 0.92
Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study. PLoS One (2016) 0.89
Retrospective evaluation of patients with elevated digoxin levels at an emergency department. Turk J Emerg Med (2016) 0.88
Omeprazole induces gastric permeability to digoxin. Dig Dis Sci (2009) 0.87
Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br J Pharmacol (2008) 0.86
Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep (2012) 0.84
Systolic heart failure in the elderly: optimizing medical management. Heart Fail Rev (2012) 0.82
Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Curr Cardiol Rev (2012) 0.82
Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med (2004) 0.82
A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol (2013) 0.81
Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. Am J Cardiol (2007) 0.81
[Drug treatment of chronic heart failure]. Clin Res Cardiol (2006) 0.80
Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol (2012) 0.80
Observational cohort study of the safety of digoxin use in women with heart failure. BMJ Open (2012) 0.80
Pharmacological treatment of chronic heart failure. Heart Fail Rev (2006) 0.79
Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Fail (2005) 0.79
"Nihilism" of chronic heart failure therapy in children and why effective therapy is withheld. Eur J Pediatr (2016) 0.78
Digitalis in heart failure! Still applicable? Z Kardiol (2005) 0.78
Necessary cautions when considering digoxin in heart failure. CMAJ (2007) 0.78
Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality. Cardiol Res Pract (2015) 0.77
Management of digoxin toxicity. Aust Prescr (2016) 0.77
Inhibiting Na+/K+ ATPase can impair mitochondrial energetics and induce abnormal Ca2+ cycling and automaticity in guinea pig cardiomyocytes. PLoS One (2014) 0.77
Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma. Oncotarget (2016) 0.77
Pharmacologic modulation of parasympathetic activity in heart failure. Heart Fail Rev (2011) 0.77
Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev (2014) 0.76
Digoxin in management of heart failure in children: Should it be continued or relegated to the history books? Ann Pediatr Cardiol (2009) 0.76
Optimal digoxin concentrations for patients with heart failure. JAMA (2003) 0.75
Clinical Characteristics and Treatment of Cardiomyopathies in Children. Curr Cardiol Rev (2016) 0.75
Inappropriate use of digoxin in patients presenting with digoxin toxicity. J Geriatr Cardiol (2015) 0.75
Optimal digoxin concentrations for patients with heart failure. JAMA (2003) 0.75
Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients. J Pharm Health Care Sci (2015) 0.75
Positive inotropes in heart failure: a review article. Heart Asia (2012) 0.75
Use of Inotropic Agents in Treatment of Systolic Heart Failure. Int J Mol Sci (2015) 0.75
Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. Heart Fail Clin (2014) 0.75
Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol (2015) 0.75
Clinical evidence review: best practice heart failure. Perm J (2007) 0.75
Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers. Clinics (Sao Paulo) (2011) 0.75
Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data. Int J Cardiol (2010) 0.75
The Effects of Pregnenolone 16α-Carbonitrile Dosing on Digoxin Pharmacokinetics and Intestinal Absorption in the Rat. Pharmaceutics (2010) 0.75
Higher serum digoxin levels were associated with increased mortality in CHF. ACP J Club (2003) 0.75
Optimal digoxin range for men is 0.5 to 0.8 ng/mL. J Fam Pract (2003) 0.75
Targeting success in heart failure: evidence-based management. Can Fam Physician (2010) 0.75
When less is more - efficacy with less toxicity at the ED50. Br J Clin Pharmacol (2017) 0.75
Serum cystatin C levels to predict serum concentration of digoxin in Japanese patients. Int J Med Sci (2006) 0.75
Digoxin toxicity: Case for retiring its use in elderly patients? Can Fam Physician (2016) 0.75
Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy (2014) 0.75
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. Br J Pharmacol (2016) 0.75
[Digitalis and theophylline: old and superfluous?]. Z Gerontol Geriatr (2013) 0.75
Chronic heart failure. Aust Prescr (2017) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA (2008) 12.36
Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Delayed time to defibrillation after in-hospital cardiac arrest. N Engl J Med (2008) 8.36
Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med (2006) 8.18
Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med (2013) 8.08
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med (2009) 6.89
Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study. Lancet (2012) 6.60
Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ (2012) 6.39
An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes (2008) 6.00
The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med (2005) 5.86
Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med (2002) 5.74
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes (2009) 5.66
Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med (2005) 5.49
An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction. Circulation (2006) 5.35
Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA (2013) 5.27
National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA (2011) 5.16
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA (2002) 4.92
Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med (2002) 4.80
National trends in use of computed tomography in the emergency department. Ann Emerg Med (2011) 4.72
The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med (2008) 4.70
An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation (2006) 4.52
Regulatory review of novel therapeutics--comparison of three regulatory agencies. N Engl J Med (2012) 4.50
Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med (2002) 4.45
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
Consequences of inadequate sign-out for patient care. Arch Intern Med (2008) 4.39
Efficacy and safety of low-carbohydrate diets: a systematic review. JAMA (2003) 4.38
Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA (2010) 4.36
Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation (2006) 4.35
Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA (2009) 4.29
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol (2004) 4.14
Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med (2001) 4.07
Evaluation of a consumer-oriented internet health care report card: the risk of quality ratings based on mortality data. JAMA (2002) 4.06
Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Time to treatment in primary percutaneous coronary intervention. N Engl J Med (2007) 3.95
Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation (2005) 3.86
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol (2006) 3.85
When choosing statin therapy: the case for generics. JAMA Intern Med (2013) 3.80
Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation (2005) 3.78
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45
Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA (2004) 3.45
Transfers of patient care between house staff on internal medicine wards: a national survey. Arch Intern Med (2006) 3.43
Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med (2002) 3.43
Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med (2008) 3.42
Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA (2006) 3.40
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J (2004) 3.37